Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAZ | P63104 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14530930 | 1.00 | YWHAZ (1.00) | YWHAZ | |
| SCHEMBL158595 | 1.00 | YWHAZ (1.00) | YWHAZ | |
| SCHEMBL14497663 | 1.00 | YWHAZ (1.00) | YWHAZ | |
| SCHEMBL13770407 | 1.00 | YWHAZ (1.00) | YWHAZ | |
| SCHEMBL29914208 | 1.00 | YWHAZ (1.00) | YWHAZ | |
| SCHEMBL14749541 | 0.94 | YWHAZ (0.90) | YWHAZ | |
| SCHEMBL14749566 | 0.94 | YWHAZ (0.89) | YWHAZ | |
| SCHEMBL26598089 | 0.94 | YWHAZ (0.88) | YWHAZ | |
| SCHEMBL13764968 | 0.90 | YWHAZ (0.81) | YWHAZ | |
| SCHEMBL26560757 | 0.89 | YWHAZ (0.80) | YWHAZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229077-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229077-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11912985-B2 | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence | THE BROAD INSTITUTE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912985-B2 | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence | THE BROAD INSTITUTE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230340467-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340467-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340465-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340465-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340466-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11795452-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230332144-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230332144-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230220374-A1 | METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE | THE BROAD INSTITUTE, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230220374-A1 | METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE | THE BROAD INSTITUTE, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-11643652-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643652-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2013031975-A1 | METHOD FOR PRODUCING INTERMEDIATE FOR BIOSYNTHESIS OF FUSICOCCIN A, AND SYNTHASE FOR USE IN SAID METHOD | DAIRI TOHRU (JP) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795452-B2 | Methods and compositions for prime editing nucleotide sequences | RNGTT, POLRMT, POLM | YWHAZ 3099/4885 |
| US-20230340465-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | YWHAZ 3088/4885 |
| US-20230340467-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | YWHAZ 3088/4885 |
| US-20230332144-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | POLRMT, RNGTT, POLM | YWHAZ 2881/4885 |
| US-20230340466-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | POLRMT, RNGTT, POLM | YWHAZ 2871/4885 |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | YWHAZ 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.